By attaching ligands or antibodies specific to cancer cell markers, SWCNTs can precisely target and bind to tumor cells. This specificity allows for the delivery of therapeutic agents directly to the malignant cells, increasing the concentration of the drug at the tumor site and improving treatment outcomes.
